GlassScriptPhysician profile
Rajeev B Patel
NPI 1174769996
$21,072.53
in general payments reported to CMS, 2019-2025
12 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,424 · 2020: $6,591 · 2021: $12K · 2022: $181 · 2023: $95.34 · 2024: $181 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $523.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $523.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $16,331.74 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Cumberland Pharmaceuticals, INC. | $3,813.58 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $247.10 | 2024-2025 | Fasenra |
| Merck Sharp & Dohme LLC | $238.07 | 2019-2025 | Keytruda |
| Fisher & Paykel Healthcare INC | $227.43 | 2022-2023 | Fisher & Paykel Healthcare |
| Astellas Pharma US INC | $76.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.86 | 2022 | |
| Chiesi USA, INC. | $26.82 | 2019-2021 | |
| Grifols USA, LLC | $24.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.03 | 2020 | |
| Genentech USA, INC. | $17.11 | 2019 | |
| Inari Medical, INC. | $15.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajeev Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.